VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

Recruiting

• Conditions: COVID-19 Disease

• Registration Number: NCT04587323
• Lead Sponsor: University of Alabama at Birmingham

Brief Summary

To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.

Detailed Description

When patients are sick with other lung infections (pneumonias) caused by viruses or bacteria there are changes in a pathway that regulates the "leakiness" the tiny airspaces inside the lungs. Even bigger changes in this pathway are seen when patients develop severe breathing difficulties (acute respiratory distress syndrome) similar to what is seen in patients who get really sick with COVID-19 disease.

There are important changes in this pathway that occur in patients who have preexisting cardiovascular (heart) disease who do not have lung infections. The investigator will evaluate these levels in patients with COVID-19 because the investigator believes that this baseline difference in pathway regulation may be one reason patients with heart disease who contract COVID-19 get sicker than patients without heart or vascular disease.

The investigator will also assess the levels of components of this pathway in patients who are less sick with those who became sick enough to require a tube to help them breathe because this is important to determine if COVID-19 lung disease has a similar effect on this pathway as other lung infections like flu and bacterial pneumonias.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2020-05-22
• Study First Submitted: 2020-09-22
• Study First Submitted QC: 2020-10-13
• Study First Posted: 2020-10-14
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-25
• Last Update Posted: 2024-03-26
• Primary Completion: 2024-12-20
• Study Completion: 2025-01-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Positive test for COVID-19 (SARS-CoV-2 infection)
• >=18 years
• Blood (plasma) specimen(s) available in the CCTS biorepository

Read More

Exclusion Criteria

• <18 years
• Lack of blood specimen

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PlGF	7-14 days after symptom onset	Plasma samples will be analyzed to measure PlGF
FGF	7-14 days after symptom onset	Plasma samples will be analyzed to measure FGF
Laboratory Assays	7-14 days after symptom onset	The primary outcome measure is the ratio of soluble fms-like tyrosine kinase receptor-1 (sFlt-1) to vascular endothelial growth factor (VEGF) which will be obtained using an immunoassay on blood samples. The specimens will be analyzed using enzyme-linked immunosorbent assay and reported as a ratio
VEGF-A	7-14 days after symptom onset	Plasma samples will be analyzed to measure VEGF-A
Tie-2	7-14 days after symptom onset	Plasma samples will be analyzed to measure Tie-2
VEGF-D	7-14 days after symptom onset	Plasma samples will be analyzed to measure VEGF-D
Flt-1	7-14 days after symptom onset	Plasma samples will be analyzed to measure Flt-1
VEGF-C	7-14 days after symptom onset	Plasma samples will be analyzed to measure VEGF-C

Trial Locations

Locations (1)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States